These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 32422341)

  • 41. Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.
    Megaly M; Glogoza M
    Scott Med J; 2020 Nov; 65(4):123-126. PubMed ID: 32807019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
    Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
    Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection.
    Salah HM; Calcaterra G; Mehta JL
    J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):503-507. PubMed ID: 32748634
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.
    Matsuzawa Y; Ogawa H; Kimura K; Konishi M; Kirigaya J; Fukui K; Tsukahara K; Shimizu H; Iwabuchi K; Yamada Y; Saka K; Takeuchi I; Hirano T; Tamura K
    Hypertens Res; 2020 Nov; 43(11):1257-1266. PubMed ID: 32820236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis.
    Lee HW; Yoon CH; Jang EJ; Lee CH
    Thorax; 2021 May; 76(5):479-486. PubMed ID: 33504565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis.
    Ssentongo AE; Ssentongo P; Heilbrunn ES; Lekoubou A; Du P; Liao D; Oh JS; Chinchilli VM
    Open Heart; 2020 Nov; 7(2):. PubMed ID: 33154144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.
    Onweni CL; Zhang YS; Caulfield T; Hopkins CE; Fairweather L; Freeman WD
    Crit Care; 2020 Jul; 24(1):475. PubMed ID: 32736573
    [No Abstract]   [Full Text] [Related]  

  • 48. Renin-angiotensin-aldosterone system and COVID-19 infection.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
    Xie Q; Tang S; Li Y
    Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ACEi/ ARB and Deaths of COVID-19 Patients.
    Azad GN; Kumar A
    Curr Hypertens Rev; 2022; 18(2):158-162. PubMed ID: 35392786
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis.
    Asiimwe IG; Pushpakom S; Turner RM; Kolamunnage-Dona R; Jorgensen AL; Pirmohamed M
    Br J Clin Pharmacol; 2021 Dec; 87(12):4534-4545. PubMed ID: 34101232
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis.
    Hasan SS; Kow CS; Hadi MA; Zaidi STR; Merchant HA
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):571-590. PubMed ID: 32918209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study.
    Alrashed AA; Khan TM; Alhusseini NK; Asdaq SMB; Enani M; Alosaimi B; Alkhani NM; Mohzari Y; Alghalbi MM; Alfahad W; Alanazi MA; Albujaidya AS; Ben-Akresh A; Almutairi M; Abraham I; Alamer A
    J Infect Public Health; 2021 Jun; 14(6):726-733. PubMed ID: 34020213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Cooper TE; Teng C; Tunnicliffe DJ; Cashmore BA; Strippoli GF
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD007751. PubMed ID: 37466151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
    Zhang L; Zeng X; Fu P; Wu HM
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
    Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
    PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
    de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
    BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.
    Yin J; Wang C; Song X; Li X; Miao M
    Am J Hypertens; 2022 May; 35(5):462-469. PubMed ID: 35512430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.
    Oussalah A; Gleye S; Clerc Urmes I; Laugel E; Callet J; Barbé F; Orlowski S; Malaplate C; Aimone-Gastin I; Caillierez BM; Merten M; Jeannesson E; Kormann R; Olivier JL; Rodriguez-Guéant RM; Namour F; Bevilacqua S; Losser MR; Levy B; Kimmoun A; Gibot S; Thilly N; Frimat L; Schvoerer E; Guéant JL
    Clin Infect Dis; 2020 Dec; 71(9):2447-2456. PubMed ID: 32623470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.